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Epidemic history of hepatitis C virus 
genotypes and subtypes in Portugal
Claudia Palladino  1, Ifeanyi Jude Ezeonwumelu1, Rute Marcelino2, Verónica Briz3, 
Inês Moranguinho1, Fátima Serejo4, José Fernando Velosa4, Rui Tato Marinho4, 
Pedro Borrego1,5 & Nuno Taveira1,6
Any successful strategy to prevent and control HCV infection requires an understanding of the 
epidemic behaviour among the different genotypes. Here, we performed the first characterization of 
the epidemic history and transmission dynamics of HCV subtypes in Portugal. Direct sequencing of 
NS5B was performed on 230 direct-acting antiviral drugs (DAA)-treatment naïve patients in Lisbon. 
Phylogenetic analysis was used for subtyping and transmission cluster identification. Bayesian 
methods were used to reconstruct the epidemic history of HCV subtypes. Sequences were analysed for 
resistance-associated substitutions (RAS). The majority of strains were HCV-GT1 (62.6%), GT3 (18.3%, 
all subtype 3a) and GT4 (16.1%). Among GT1, the most frequent were subtypes 1a (75.5%) and 1b 
(24.5%). Polyphyletic patterns were found in all but 12 lineages suggesting multiple introductions of the 
different subtypes in this population. Five distinct epidemics were identified. The first significant HCV 
epidemic in Portugal occurred between 1930s and 1960s, was caused almost exclusively by GT1b and 
was likely associated with blood transfusions. Rapid expansion of GT3a occurred in the 1960s and GT1a 
in the 1980s, associated with intravenous drug use. The most recent epidemics were caused by GT4a 
and GT4d and seem to be associated with the resurgence of opioid use. The C316N substitution was 
found in 31.4% of GT1b-patients. Close surveillance of patients bearing this mutation and undergoing 
dasabuvir-based regimens will be important to determine its impact on treatment outcome.
Hepatitis C virus (HCV) infection continues to be a major public health problem globally despite the intro-
duction of new treatment modalities based on a combination of direct-acting antiviral drugs (DAA). Globally, 
around 71 million people (1.1% of world population) are chronically infected individuals1.
The high genetic heterogeneity exhibited by HCV has given rise to seven major genotypes (1–7)2 that differ 
on average by 30% at nucleotide level3, and 86 subtypes4 that differ between 15–25% at nucleotide level3. It is still 
unclear if HCV genotypes originated from a single cross-species transmission and subsequently diverged within 
the human host or from separate zoonotic sources in different regions5.
Genotype (GT) 1 accounts for the majority of infections (44%) globally with an extended spatial distribution 
mainly in upper-middle income and high-income countries6. GT3 is the second most prevalent genotype (25%) 
and is mainly found in lower middle-income countries, mainly in South Asia, and GT4 represents 15% of all HCV 
infections and is common in resource-constrained countries, mainly in North and Central Africa and the Middle 
East6. There are indications that the different genotypes have existed in restricted geographic areas prior to the 
twentieth century, GT1 and GT2 in West Africa7–9; GT3 in the Indian subcontinent10; GT4 in Central Africa11; 
GT6 in Southeast Asia12; and GT7 in the Democratic Republic of Congo13. The global dissemination of GT1 and 
GT3 seem to have occurred between 1940 and 1980 through blood transfusion, unsafe medical practices and 
injecting drug use14–17.
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The huge genetic variability of HCV brings challenges to host immune control, to the management of 
HCV-infected patients, and to the development of pan-genotypic treatments18. Important differences have been 
identified in the susceptibility of HCV genotypes to antibody neutralization indicating that a successful vaccina-
tion strategy has to take into consideration genotype distribution worldwide19,20. Regarding treatment, treatment 
of chronic HCV infection with peginterferon + ribavirin showed variable efficacy depending on the genotype 
with sustained virological response (SVR) rates of 42–58%21–23, 80%, 66%24 or 63–69%25 for GT1, GT2, GT3 
or GT4, respectively. The current treatment landscape based on a combination of direct-acting antiviral drugs 
(DAA) has increased dramatically the cure rate of chronic HCV infection26. Two drugs targeting the viral NS5B 
RNA polymerase have been approved in Europe and the US for clinical use, the nucleotide analogue sofosbuvir 
and the nonnucleoside inhibitor dasabuvir27,28, while others are in the pipeline29. Sofosbuvir-based combination 
treatment resulted in SVR rates of 50–93% in six phase 3 trials30–33. Since 2014, the combination of sofosbu-
vir/simeprevir/ribavirin and the new fixed-dose combinations ledipasvir/sofosbuvir and sofosbuvir/velpatasvir 
resulted in SVR rates of 92–100% in trials enrolling patients infected with HCV GT134–40 and 85–100% in other 
genotypes40–43. Dasabuvir co-packaged with ombitasvir/paritaprevir/ritonavir achieved SVR rates of 89–100%44. 
The presence of resistance-associated substitutions (RAS) as natural polymorphisms in the NS5B gene affects 
HCV susceptibility to sofosbuvir and dasabuvir and may limit the clinical effectiveness of DAA combinations 
containing these drugs45,46.
Despite the enormous progress made in the treatment of HCV, a recent projection performed in Germany 
indicates that a substantial number of patients (7%) will fail to achieve SVR and will have limited retreatment 
options47. In addition, people who are cured are at risk of HCV reinfection. Incidence of reinfection varying 
between 7–13/100 person-years has been reported among gay and bisexual men in Europe48–50. Hence, it is neces-
sary to be continuously vigilant about the main factors that may affect the success of HCV treatment in any given 
location, which are the genotype of the circulating HCV strains and the presence of natural polymorphisms and 
mutations associated with drug resistance.
In Portugal, there is scarce epidemiological research on HCV and prevalence data are limited. Among the 
European countries, Portugal has the highest prevalence rate of HCV infection (83.5%) in people who inject 
drugs (PWID)51, while in the prison population, the prevalence of HCV in 2014 was 10.7%52. A recent nationwide 
cross-sectional survey enrolling 1,685 adults in 2012–2014, reported a low HCV prevalence (0.54%; 0.2–0.9)53 
lower than the previous estimates of 1–1.5%54,55. The possible underrepresentation of high-risk groups likely 
explains the remarkable low HCV prevalence in this recent survey. To comply with the global commitment for 
hepatitis elimination56, at the beginning of 2015, the Portuguese Ministry of Health implemented a national plan 
of universal access to HCV treatment. In the frame of this programme, named Portal of Hepatitis C, more than 
11,700 patients have initiated combinations of sofosbuvir-based treatments and 6,639 patients have been cured, 
representing 96.5% of those who have already completed the treatment57.
Based on four previous studies performed between 1998 and 2014, the majority of HCV infections in Portugal 
are caused by GT1 followed by GT3, GT4 and GT258–63. The origin, epidemiological history and transmission 
dynamics of these genotypes in Portugal have not been investigated. Hence, the aims of the present study were 
to characterize the origin, epidemiological history and transmission dynamics of HCV genotypes and subtypes 
circulating in Portugal, and to assess the prevalence of natural polymorphisms at the NS5B gene that may impact 
susceptibility to sofosbuvir and dasabuvir.
Results
HCV diversity and transmission dynamics. A total of 230 patients were included in this study. Overall, 
59.1% (n = 136) of subjects were men and had a median age of 41 years (IQR: 49–36). The genotyping results 
showed a majority of GT1 (62.6%; n = 144), followed by GT3 (18.3%; n = 42) and GT4 (16.1%; n = 37), while 
GT2 was the least frequent (3.0%; n = 7) (Table 1). Among patients harbouring GT1, the most frequent subtype 
was 1a (75.5%, n = 108) followed by GT1b with a 3.1-fold lower prevalence (24.5%, n = 35), (P < 0.0001); only 
one patient was infected with GT1g (0.4%). Among patients with GT2, 1.3% (n = 3) of the total population had 
an undetermined subtype, while GT2a and GT2c were each found in 0.9% (n = 2) of the total population. All 
GT3 were subtype 3a. Among patients with GT4, the most represented subtypes were GT4a, with 10.4% of the 
total population (n = 24) and GT4d (4.3%; n = 10); GT4b, GT4f and GT4k were found in one (0.4%) patient each 
(Table 1, Fig. 1).
The GT1a clade II was significantly more prevalent than clade I (78.7%; n = 85/108 vs. 21.3%; n = 23/108; 
P < 0.0001). Interestingly, when the GT1a lineages assigned by phylogenetic analysis were analysed with the 
geno2pheno[HCV] algorithm, 25 sequences had inconsistent clade results (Table S1). Likewise, inconsistent results 
were observed for two sequences that were classified as GT2 and GT4b by phylogenetic analysis and as GT2b and 
GT4w by geno2pheno[HCV]. Except for 12 HCV lineages which segregated into six transmission clusters (a pair 
each for GT1a, GT1b, GT2, GT2a, GT3a and GT4a), polyphyletic patterns were found suggesting multiple and 
old introductions of the different HCV subtypes in this population (Fig. 1).
Origin and epidemiologic history of HCV strains circulating in Portugal. The dates of the most 
recent common ancestors (MRCA) of the various HCV subtypes circulating in the Portuguese population were 
estimated in BEAST under an uncorrelated lognormal relaxed molecular clock with a Bayesian skyline plot (BSP) 
coalescent demographic model (Table 2). According to our estimates, the ancestor of the 1a strains present in 
Portugal dated back to 1950 (95% HPD: 1922, 1973) whereas that of 1b dated back to 1946 (95% HPD: 1847, 
1965) and 3a to 1963 (95% HPD: 1947, 1977). For genotype 4 strains, similar ancestor dates were obtained [GT4a, 
1988 (95% HPD: 1980, 1995); GT4d, 1982 (95% HPD: 1964, 1995)].
To investigate the epidemiologic history of the different HCV subtypes in the Portuguese population, BSP 
reconstruction was made for each subtype (Fig. 2).
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The data indicates that the first significant increase in HCV prevalence in Portugal occurred in the first half 
of the 20th century (the 1930s) and was caused almost exclusively by GT1b until the 1960s. At this time a second 
epidemic emerged caused by GT3a; a third epidemic caused by GT1a emerged during the 1980s. The first two 
epidemics caused by GT1b and 3a reached equilibrium at the end of the 1980s, whereas the 1a epidemics contin-
ued to grow rapidly (growth rate: 0.308 Ln of number of effective infections per year) until the end of the 1990s 
when it reached equilibrium. The most recent epidemics were caused by GT4a and GT4d and while the GT4d 
epidemics seems to have reached an equilibrium GT4a epidemics is still expanding at the present although at a 
lower rate relative to the epidemic phase of GT1a and GT3a (Fig. 3).
Baseline polymorphisms and RAS at the NS5B domain. The majority of patients (93.9%; n = 216) 
harbored viruses with baseline NS5B polymorphisms (Tables 3, 4 and S2). The percentage of patients with poly-
morphisms within each genotype/subtype was 60.9% for GT1a clade I, 97.6% for GT1a clade II, 91.4% for GT1b 
and 100% for all the other genotypes/subtypes (Table 1). Within GT1a, more patients with clade II harbored 
polymorphisms as compared to clade I (97.6%; n = 83/85 vs 60.9%; 14/23; P < 0.0001). The only RAS identified 
was C316N and was observed in 31.4% (n = 11/35) of the patients with GT1b. This amino acid substitution has 
been shown to confer a 5-fold resistance to the nonnucleoside RdRp palm-1 inhibitor (dasabuvir) in GT1b64. In 
addition, amino acid substitutions on scored position for sofosbuvir, V321I, V321I/V and V321S/L were observed 
in one patient each harbouring GT1a clade I, GT1a clade II and GT3a respectively (Tables 3, 4 and S2).
Discussion
We applied phylogenetic and phylodynamic analysis to NS5b sequences obtained from DAA naïve HCV infected 
patients to make the first characterization of the origin, diversity and epidemiologic history of HCV in Portugal. 
Like in previous studies, the most prevalent HCV variants were GT1a, representing almost half of the sequences 
analyzed, followed by GT3a and GT1b58–62. These genotypes are responsible for the majority of the HCV cases 
globally63,65,66.
According to our estimates, GT1b has caused a slowly growing but extended epidemic from the 1930s to the 
1990s. This epidemic preceded all others by three decades and its features are consistent with widespread unsafe 
needle practices at the beginning of the 20th century and contaminated blood transfusions which stopped only 
after the discovery of HCV in 1989 and the subsequent screening of all blood donations for HCV67,68. The increase 
in intravenous drug use in the 1960s has likely sparked the second major HCV epidemic in Portugal which was 
caused by GT3a and went through the beginning of the 1980s. The fastest growing HCV epidemic in Portugal 
occurred during the 1980s and 1990s and was caused by GT1a. The GT1a was likely driven by PWID which 
increased dramatically in the late 1980s and 1990s up to 1% of the Portuguese population due to the rapid social 
and cultural changes that followed the revolution of 1974 and the increasing availability of heroin69–71.
We observed a relatively high (16.1%) prevalence of GT4 among the study population, that is about 
three-fold higher than the estimated prevalence for Western Europe65,66. Similar results were obtained recently in 
HCV-infected inmates in Portugal (13% GT4)62. In addition to GT4a, the most prevalent in our study group, and 
GT4b and GT4d that have already been reported in Portugal61,62,72, we also identified one isolate classified as GT4f 
and one as GT4k. To the extent of our knowledge, this is the first report of these variants in Portugal. Globally, 
GT4 has been more prevalent in some countries of Northern and Central Africa and the Middle East11, but there 
are indications that GT4 is becoming increasingly prevalent in Europe, mainly among PWID61,73,74.
It was interesting to find that unlike GT1 and GT3 that caused endemic localized infections during decades 
before becoming generalized, GT4a became epidemic almost immediately after being introduced in Portugal, 




% of patients with polymorphisms 
within each genotype/subtype
N = 230 (%) N = 216 (93.9%) %*
1a clade I 23 (10.0) 37 (33–40) 14 (6.5) 60.9
1a clade II 85 (37.0) 40 (36–47) 83 (38.4) 97.6
1b 35 (15.2) 53 (36–60) 32 (14.8) 91.4
1 g 1 (0.4) 53 1 (0.5) 100.0
2 3 (1.3) 57 3 (1.4) 100.0
2a 2 (0.9) 44 2 (0.9) 100.0
2c 2 (0.9) 47 2 (0.9) 100.0
3a 42 (18.3) 42 (35–48) 42 (19.4) 100.0
4a 24 (10.4) 40 (34–46) 24 (11.1) 100.0
4b 1 (0.4) 69 1 (0.5) 100.0
4d 10 (4.3) 42 (39–46) 10 (4.6) 100.0
4 f 1 (0.4) 60 1 (0.5) 100.0
4k 1 (0.4) 46 1 (0.5) 100.0
Table 1. Relative frequencies of the HCV genotypes, subtypes and NS5B polymorphisms in patients included 
in the current study. #IQR, interquartile range; *Relative to the total number of patients with polymorphisms 
(n = 216).
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likely in 1980, and this epidemic may still be growing at a relatively fast rate. The reason for this is unclear as the 
mode of transmission was known only for 27% of our patients. GT4a dominates the HCV epidemic in Egypt 
and the main risk factor for its origin and transmission has been unsafe medical practices75. Similar to GT4a, the 
epidemic history of GT4d indicates a recent introduction and a progressive epidemic in the Portuguese popula-
tion. In Portugal, healthcare related HCV infections are exceedingly rare and GT4a and GT4d have been found 
in relatively high frequencies (11.3% and 12.1%, respectively) in PWID analysed in a similar period (2008–2009) 
in Lisbon61. In addition, 83.3% of GT4a (n = 6) and 75% of GT4d (n = 4) infected patients for which we have 
information on transmission risk were PWIDs. We, therefore, believe that injecting drug use is the main mode of 
transmission of GT4 in Portugal.
Figure 1. Phylogenetic analysis of NS5B gene sequences from HCV infected patients attending the Hospital 
Santa Maria, Lisbon, Portugal. The sequences from Portuguese patients are colored in red and reference HCV 
sequences are colored in black. HCV genotypes and subtypes are indicated with different colored strips with 
subtype 6 as an outgroup. The bootstrap values supporting the internal branches defining a genotype, subtype 
or clade are shown at the nodes as blue-filled circles with size corresponding to the magnitude of bootstrap 
values (only values between 70 and 100% are shown). Bootstrap values of 70% or greater provide reasonable 
confidence for assignment of an individual sequence to one or the other genotype. The scale represents number 
of base substitutions per site. Identified transmission clusters (pairs) are shaded in grey.
Dataset
Dates of MRCA* (95% HPD 
interval)
Subtype 1a (n = 108) 1950 (1922, 1973)
Subtype 1b (n = 35) 1946 (1847, 1976)
Subtype 3a (n = 42) 1963 (1947, 1977)
Subtype 4a (n = 24) 1988 (1980, 1995)
Subtype 4d (n = 24)** 1982 (1964, 1995)
Table 2. Estimated dates of MRCAs for HCV subtypes identified in the current study. *Mean estimates of most 
recent common ancestor (MRCA) dates in calendar years. **Contains additional GT4d sequences (n = 14) 
from a previous study in Portugal.
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The prevalence of GT2 in the study group was only 3.2%, about one-third lower than previously reported data 
from Western Europe66. In particular, the prevalence of GT2a, generally considered as an epidemic subtype, was 
less than 1%. A similar low prevalence was also observed for GT2c, in contrast to the high frequency (37.5%) 
previously reported among a limited number (n = 64) of liver biopsies at the Portuguese tertiary Hospital Santa 
Maria, the same healthcare setting attended by our study group60.
Figure 2. Epidemic history of HCV subtypes in Lisbon, Portugal. Bayesian skyline plot (BSP) showing the 
epidemic history of the most prevalent HCV subtypes (1a, 1b, 3a, 4a and 4d) found in patients attending the 
Hospital Santa Maria of Lisbon, Portugal. The solid blue line represents the changes in the mean effective 
population size through time on a log10 scale, with the blue shaded area corresponding to the 95% highest 
posterior density (95% HPD) interval. The bold dotted and faint dashed black vertical lines represent the 
median and upper boundaries of the time to the most recent common ancestor (MRCA) respectively. For GT4d, 
plots were built using additional sequences from Portugal (n = 14) retrieved from GenBank.
Figure 3. Exponential mean growth rates for the most prevalent HCV subtypes (1a, 1b, 3a, 4a and 4d*) 
found in the current study. Linear regression equations were derived from the mean growth rates within the 
exponential phase of the Bayesian skyline plots (BSP) of each subtype as shown in Fig. 2. *Contains additional 
GT4d sequences (n = 14) from a previous study in Portugal.
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Genotype or subtype
1a clade I N (%)
1a clade
II N (%) 1b N (%) 1 g N (%) 2 N (%) 2a N (%) 2c N (%)
AA 30 169 68 4 34 10 33
231 S231R 1 (3.3) S231G/H/N 14 (8.3) S231A/N 19 (27.9) R231S 1 (3.0)
235
238 S238A 1 (3.0)
241 Q241L 1 (2.9) R241Q 2 (20.0) L241Q 1 (3.0)
242 C242S 1 (3.3) S242C 1 (3.0)
244 D244N 1 (3.3) S244D 1 (3.0)
245 L245M 1 (2.9)
246 S246P 3 (8.8) P246T 2 (20.0) P246D 1 (3.0)
247 K247E 3 (8.8) E247P 1 (3.0)
248 Q248K 1 (3.3) E248Q 1 (3.0)
249 T249A 3 (8.8)
250 H250R 2 (20.0)
251 V251I 1 (3.3) I251V 1 (25.0) T251V 1 (3.0)
252 A252V 6 (8.8) V252A 3 (8.8)
254 K254R 6 (20.0) R254K 8 (11.8) R254K 1 (25.0) H254K 1 (3.0)
258
262 I262V 5 (7.4)
266 M266L 1 (3.0)
267 F267L 2 (20.0)
270 R270K 7 (4.1) K270R 1 (3.0)
271
272 Q272E 1 (3.0)
273 A273S 1 (2.9) S273N 1 (3.0)
276
282
285 L285F 3 (8.8)
289 M289C 1 (3.0)
293 I293L 1 (2.9)
296
297 V297I 1 (3.0)
300 R300Q 7 (23.3) Q300K/L/R 40 (23.7) S300A/T 10 (14.7) S300L 3 (8.8) K300R 3 (9.1)
303
304 N304R 1 (3.0)
305
307 K307G 1 (25.0)
308 I308V 1 (2.9) I308L 1 (3.0)
309 Q309R 5 (16.7) R309Q 23 (13.6) Q309R 6 (8.8) I309N 2 (5.9) I309V 2 (20.0) V309Q 1 (3.0)
310 D310N 1 (3.3) K310N 3 (8.8) A310D 1 (3.0)
311 P311C 1 (3.0)
312
313
316 C316N* 11 (16.2)
321 V321I* 1 (3.3)
322
324 S324C 1 (3.0)
327 A327G/M 3 (10.0) Q327A 1 (3.0)
328
329 I329T 3 (8.8) V329A/V 2 (6.1)
330 Q330R 1 (3.3) Q330P 8 (4.7) E330Q 1 (3.0)
333 A333E 1 (3.3) E333A 1 (3.0)
334 R334Q 2 (5.9) R334A 1 (3.0)
Continued
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Concerning the other less prevalent HCV variants, we identified one individual harbouring GT1g. To the best 
of our knowledge, this is the first report of HCV-GT1g in Portugal. In Europe, the first partial sequences of GT1g 
were derived in 1994–1995 from HCV chronically-infected German patients who were probably immigrants 
from Egypt and Sudan76. More recently, the first complete genome of a GT1g isolate derived from a Spanish 
patient was published77.
Recent studies have highlighted distinct geographic distributions of the two clades of GT1a, with clade I being 
more prevalent in the United States and both clades equally distributed in Europe78,79. Furthermore, a recent 
in-depth phylogenetic analysis has found three distinct sub-clades within clade I80. In the present study, that 
represents the first assessment of clades in Portugal, we found a four-fold higher prevalence of clade II than clade 
I, and the majority of polymorphisms associate to the former clade. Interestingly, the prevalence of clade I among 
the patients included in the present study was similar (21%) to that recently observed in DAA-naïve subjects in 
Spain81 but it was significantly lower than in other European countries (e.g. 48% in Italy and 67% in France)79. 
This may indicate a difference in the temporal spread of the HCV-GT1a clades in Portugal as compared to other 
European countries where both clades are equally distributed.
Baseline NS5B RAS to sofosbuvir has been rarely detected in clinical trial settings82,83 and only 0.1% of 
sequences from all genotypes present in the Los Alamos HCV sequence database harbor RAS to this DAA84. 
Consistent with this, we have not found RAS to sofosbuvir in our patients. On the other hand, the C316N RAS 
was found in 31% of GT1b-infected patients. This mutation confers low-level resistance to dasabuvir and has been 
reported in patients failing treatment with sofosbuvir85,86. The relatively high prevalence of C316N in our patients 
is in line with previous reports showing a prevalence of C316N ranging from 11% to 40% in patients with GT1b 
enrolled in clinical trials, and this mutation was more frequent among European subjects than among those from 
the United States87,88. It should be noted that in the AVIATOR trial that evaluated ritonavir-boosted paritaprevir, 
ombitasvir and dasabuvir, the C316N RAS at baseline had no significant impact on treatment outcome87.
We observed the polymorphism L285F in GT2 which has not been previously reported in the Los Alamos 
databases as RAS84. This mutation was reported in 2017 in a study assessing the genetic heterogeneity of NS5B by 
ultra-deep pyrosequencing in patients harbouring GT3a not achieving SVR. Interestingly, the L285F polymor-
phism represented a minor substitution at baseline but was enriched after virological failure89. The significance 
of this mutation is still unclear and needs further investigation. Overall, these data suggest that sofosbuvir and 
dasabuvir can be used in first-line treatment regimens in Portugal.
Two main limitations should be mentioned. First, our study was based on partial sequences of NS5B which 
prevented us from examining all RAS in NS5B. Second, the mode of HCV transmission was known only for 27% 
of the study group preventing us from including this variable in the transmission cluster analysis and from mak-
ing a more detailed investigation of the risk factors driving the different HCV epidemics in Portugal.
In summary, five distinct epidemics caused by different HCV subtypes were identified over time in Portugal. 
The first was caused by GT1b, occurred during the 1930s and the 1960s and was likely associated with contam-
inated blood transfusions. The second and third epidemics were caused by GT3a in the 1960s and GT1a in the 
1980s and were likely associated with widespread use of intravenous drug use. The most recent HCV epidemics 
in Portugal were caused by GT4a and GT4d and seem to be associated with the resurgence of opioid use. The 
C316N substitution causing low-level resistance to dasabuvir was found in 31.4% of GT1b-infected patients. 
Close surveillance of patients bearing this mutation and undergoing dasabuvir-based regimens will be important 
to determine its impact on treatment outcome.
Genotype or subtype
1a clade I N (%)
1a clade
II N (%) 1b N (%) 1 g N (%) 2 N (%) 2a N (%) 2c N (%)
335 C335A/G/S 77 (45.6) S335N/R 3 (4.4) S335N 1 (25.0) N335S 1 (3.0)
336
337




Table 3. Baseline polymorphisms and amino acid substitutions reported to reduce susceptibility to sofosbuvir 
and/or dasabuvir in NS5B of HCV strains (GT1 and GT2) found in the current study. Notes: Only polymorphic 
sites whose frequency is above 2% are shown; see Table S3 for the complete dataset of all polymorphisms and 
mutations. AA, amino acid position; asterisks indicate resistance associated substitutions (RAS) or substitution 
on scored position, as detailed below. V321I and V321I/V, amino acid substitutions on scored position for 
sofosbuvir (according to data of GT1a). V321S/L, amino acid substitutions on scored position for sofosbuvir 
(according to data of GT3). C316N, RAS: amino acid substitutions reported to reduce the susceptibility of HCV 
GT1b to nonnucleoside RdRp palm-1 inhibitor (dasabuvir); EC50 (fold change compared to wild-type replicon) 
is 2–20.
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Genotype or subtype
3a N (%) 4a N (%) 4b N (%) 4d N (%) 4 f N (%) 4k N (%) 
AA 117 186 9 35 N = 5 (%) N = 4 (%)
231 K231R 9 (25.7)











251 K251R 1 (25.0)
252
254 T254A/S 15 (8.1)
258 D258E 22 (11.8)
262
266 254 T254A/S 15 (8.1)
267 H267R/Y 4 (2.2) Y267F 1 (11.1) H267Y 1 (20.0)
270 K270R 6 (17.1)
271
272 A272D/G/T 5 (4.3)
273
276 I276T/V 8 (22.9)
282 T282S 24 (12.9)
285 Y285F 1 (11.1) F285Y 3 (8.6) Y285F 1 (20.0)
289
293 L293M 1 (2.9)
296 Y296F 9 (7.7)
297 I297L 1 (11.1)
300 S300N 2 (5.7)
303
304 K304R 17 (14.5) R304K 24 (12.9) K304R 1 (11.1)
305
307 N307G 40 (34.2) A307G 24 (12.9) G307R 4 (11.4)
308
309 K309R 2 (5.7)
310 N310D 1 (11.1)
311 T311Y 1 (11.1)




322 V322I 1 (11.1)
324 T324A 1 (25.0)
327 D327G 3 (2.6)
328 G328S 1 (25.0)
329
330 D330E/N/T 13 (11.1) E330D 9 (4.8) D330E 1 (20.0) E330D 1 (25.0)
333 R333G/K 8 (6.8) G333K 1 (11.1)
Continued
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Methods
Study Design and Patients. This was a retrospective observational cross-sectional study of consecutive 
HCV-infected patients seen between November 2007 and July 2009 at the Department of Gastroenterology and 
Hepatology of the Hospital de Santa Maria in Lisbon which is the main reference center for HCV infection in 
Portugal. The STROBE checklist was used to help design and conduct the study90. Eligibility criteria were: adults 
(≥18 years of age) who had a diagnosis of HCV infection based on detectable viral load (using the COBAS 
AMPLICOR HCV MONITOR test, version 2.0 kit of Roche or the Artus® HCV RG RT-PCR Kit of QIAGEN) and 
were DAA naïve. Stored plasma samples were retrieved from 230 patients (Table S3).
Ethics. Informed consent was obtained from all subjects. The study was conducted in accordance with the 
Declaration of Helsinki, as revised in 2013, and was approved by the Institutional Review Board of Santa Maria 
Hospital (ref. 245/15 of July 30, 2015).
Amplification and sequencing of HCV NS5B. Viral RNA was extracted from plasma with the 
QIAmp Viral RNA Mini kit (Qiagen, Hilden, Germany) and a 372 bp region of NS5B gene corresponding to 
the Okamoto region was amplified using Titan One Tube RT-PCR System (Roche Diagnostics) with the prim-
ers HCV_FW1 [5′-CCCGCTGYTTTGACTCVACNGT-3′, location in GT1a isolate H77 (GenBank accession 
number AF009606), 8264–8285] and HCV_RV1 (5′-CCTRGTCATAGCCTCCGTGAA-3′, location 8636–8616). 
Amplification was programmed as follows: 2 min at 94 °C and 40 cycles with 1 min at 94 °C; 30 sec at 59 °C and 
45 sec (plus 5 sec per min) at 68 °C, and finally, 7 min at 68 °C in the GeneAmp9700 Thermal Cycler. Negative and 
positive controls were included in all amplification procedures. PCR products were visualized by UV irradiation 
after electrophoresis on a 2% agarose gel with ethidium bromide. Amplicons were purified with JetQuick PCR 
Product Purification Spin Kit (GenoMed). Thereafter, the sequencing reaction was performed with the same 
primers used for amplification and Sanger sequencing was performed (ABI PRISM 3100-Avant Analyser, Applied 
Biosystems, Foster City, CA) in the following conditions: 1 min at 96 °C and 25 cycles of 10 sec at 96 °C, 5 sec at 
56 °C and 4 min at 68 °C (with a sensitivity threshold of approximately 25%)91.
HCV genotype and subtype assignment. This study includes 230 partial sequences of the NS5B region 
derived from HCV-infected patients. Sequences were 372 nucleotides in length corresponding to positions 8264 
to 8636 in reference isolate H77 (GenBank under accession number AF009606)92. Table S4 lists the boundaries of 
the sequences analysed. The nucleotide sequences were aligned with MAFFT algorithm93 as implemented in the 
HIVAlign tool hosted at Los Alamos HIV Database (https://www.hiv.lanl.gov/) and edited using SeaView94. HCV 
subtyping was performed using COMET HCV subtyping tool95 and Oxford HCV subtyping tool96,97. HCV-GT1a 
lineages (clade I and clade II) were confirmed by geno2pheno[HCV] (Bonn, Germany; http://hcv.geno2pheno.
org/). For HCV subtyping by phylogenetic analysis, nucleotide sequences from reference HCV isolates from 
each genotype, subtype and clade were retrieved from the HCV Los Alamos Database (https://hcv.lanl.gov/
content/index) and International Committee on Taxonomy of Viruses (https://talk.ictvonline.org/ictv_wikis/
flaviviridae/w/sg_flavi/56/hcv-classification) and were aligned with the Portuguese sequences using MAFFT. A 
Maximum likelihood (ML) tree was reconstructed under a GTR + Г nucleotide substitution model and 1000 
bootstrap replicates as implemented in raxMLGUI v1.598. The final phylogenetic tree was edited with the graphic 
resources contained in iTol v4.0.399.
Genotype or subtype
3a N (%) 4a N (%) 4b N (%) 4d N (%) 4 f N (%) 4k N (%) 
334
335
336 P336S 20 (10.8)
337 R337G 14 (12.0)
338
339
342 S342G 1 (20.0)
345 E345Q 21 (11.3) E345Q 1 (20.0)
Table 4. Baseline polymorphisms and amino acid substitutions reported to reduce susceptibility to sofosbuvir 
and/or dasabuvir in NS5B of HCV strains (GT3 and GT4) found in the current study. Notes: Only polymorphic 
sites whose frequency is above 2% are shown; see Table S3 for the complete dataset of all polymorphisms and 
mutations. AA, amino acid position; asterisks indicate resistance associated substitutions (RAS) or substitution 
on scored position, as detailed below. V321I and V321I/V, amino acid substitutions on scored position for 
sofosbuvir (according to data of GT1a). V321S/L, amino acid substitutions on scored position for sofosbuvir 
(according to data of GT3). C316N, RAS: amino acid substitutions reported to reduce the susceptibility of HCV 
GT1b to nonnucleoside RdRp palm-1 inhibitor (dasabuvir); EC50 (fold change compared to wild-type replicon) 
is 2–20.
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Transmission cluster analysis. Transmission clusters (TCs: include pairs and clusters ≥3) were identified 
in the ML tree using Cluster picker v1.2.3100 with thresholds for bootstrap supports and genetic distances set at 
90% and 4.5% respectively. A sensitivity analysis was also performed to evaluate the influence of bootstrap sup-
port (70%, 80% and 90%) and genetic distance thresholds (1.5%, 3.0% and 6.0%) on the clustering101,102.
Bayesian evolutionary analysis: Time-scaled phylogeny. Bayesian phylogenetic trees were recon-
structed using the Bayesian Evolutionary Analysis by Sampling Trees software package (BEAST v1.10)103 for 
HCV subtype datasets containing at least 10 dated-sequences spanning the sampling years 2007–2009 (1a, 1b, 
3a, 4a and 4d). To improve the evolutionary estimates of GT4d, 14 additional GT4d sequences (sampling years 
2008–2009) previously reported in Portugal61 were retrieved from the Los Alamos database. A two-codon par-
titioning model (SRD06 model)104, HKY + 4Г nucleotide substitution model, and an uncorrelated lognormal 
relaxed molecular clock (UCLD) with a Bayesian skyline plot (BSP) coalescent tree prior were selected for the 
Bayesian analysis. To estimate the date of the most recent common ancestor (MRCA) and the population growth 
dynamics of the HCV epidemic in Portugal, we specified a Normal prior distribution on the UCLD mean rate 
parameter (0.001 ± 0.0001 substitutions/site/year)11,105,106. For each dataset, three independent MCMC chains 
were run for 100 million generations with states sampled every 10,000 generations. Log files were combined using 
Logcombiner to ensure sufficient convergence (ESS ≥ 200) as monitored in Tracer v1.7 (http://tree.bio.ed.ac.uk/
software/tracer/) with 10% of posterior samples discarded as burn-in. Maximum clade credibility (MCC) trees 
were summarized using tree annotator and tree visualization was implemented in Figtree v1.4.3 (http://tree.bio.
ed.ac.uk/software/figtree/). To approximate the population growth rate of the epidemic history for each HCV 
subtype, we performed a linear regression analysis during the exponential growth phase of the BSP curves. The 
mean exponential growth rates were determined as the slope of the linear regression curves obtained by plotting 
the mean estimates of the effective population size in the natural logarithmic scale against time (years) in the R 
software.
Resistance-associated substitutions (RAS) and polymorphisms. The NS5B gene was reviewed to 
determine the amino acid substitutions reported to reduce the susceptibility of different HCV genotypes or sub-
types to DAA according to the latest review of Pawlotsky 2016, the European and American guidelines107–110. 
Sofosbuvir-specific clinically relevant RAS were L159F, S282T/R, L320I/F/V and V321A, depending on genotype/
subtype, and dasabuvir-specific clinically relevant RAS were L314H and C316H/N/Y/W (only for GT1). Other 
polymorphisms in positions associated with resistance to these drugs were also assessed.
To identify RAS and polymorphisms in NS5B of our patients, the sequences were translated to amino acids 
and aligned against the following reference sequences: GenBank accession number AF009606 for GT-1a clade 
I, HQ850279 for GT-1a clade II, EU781827 for GT-1b, AM910652 for GT-1g, KC197237 for GT-2, D00944 for 
GT-2a, D50409 for GT 2c, D17763 for GT-3a, Y11604 for GT-4a, FJ462435 for GT-4b, DQ418786 for GT-4d, 
EF589161 for GT-4f, and EU392173 for GT-4k. Degenerate codons were present in some individuals reflecting 
the presence of quasiespecies. When these codons were present in positions associated with drug resistance all 
translation possibilities were considered.
Statistical Analysis. Categorical variables were analysed using the chi-squared test or Fisher’s exact test. 
P-values were 2-tailed and statistical significance was defined as P < 0.05. Statistical analyses were performed 
using the SPSS software Version 22.0 (IBM Corp, Chicago, Armonk, NY, USA).
GenBank accession numbers. The HCV sequences were deposited in GenBank under accession num-
bers MG821636-MG821865. The accession numbers for the additional GT4d sequences include: FN401072, 
FN401080, FN401090, FN401092, FN401095, FN401120, FN401132, FN401142, FN401146, FN401154, 
FN401157, FN401177, FN401182, FN401193.
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